Pluri Inc. logo
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
July 25, 2022 01:00 ET | Pluristem Therapeutics, Inc.
As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing...
Pluristem Therapeutics Inc. Logo
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
July 13, 2022 06:00 ET | Pluristem Therapeutics, Inc.
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration:...
Pluristem Therapeutics Inc. Logo
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
March 28, 2022 03:00 ET | Pluristem Therapeutics, Inc.
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at:...
Pluristem Therapeutics Inc. Logo
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
March 23, 2022 07:30 ET | Pluristem Therapeutics, Inc.
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced...
Eyal Rosenthal, photographed by Jim Vetter
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
March 08, 2022 07:12 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”),...
Pluristem Therapeutics Inc. Logo
Pluristem CEO Issues Shareholder Update
March 02, 2022 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
Pluristem Therapeutics Inc. Logo
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
February 24, 2022 07:00 ET | Pluristem Therapeutics, Inc.
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food techPluristem and Tnuva are...
Yaky Yanay, CEO and President of Pluristem, photography - Rami Zarnegar
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
January 10, 2022 03:00 ET | Pluristem Therapeutics, Inc.
Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and...
Pluristem Therapeutics Inc. Logo
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
December 27, 2021 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its...
Pluristem Therapeutics Inc. Logo
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
November 15, 2021 07:10 ET | Pluristem Therapeutics, Inc.
Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event...